Ellington Management Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Ellington Management Group’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-36,000	Closed	-$127K	–	856
2015 Q4	$127K	Buy	36,000 +6,400	+22%	+$26.8K	0.04%	526
2015 Q3	$149K	Buy	+29,600	New	+$170K	0.04%	626
2015 Q2	–	Sell	-10,400	Closed	-$73K	–	1058
2015 Q1	$73K	Buy	+10,400	New	+$75.3K	0.02%	649

Other funds holding PDLI

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ellington Management Group's PDLI Position: Q1 2016 in Review

Ellington Management Group sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 36,000 shares — an estimated $127K sold.

Ellington Management Group first reported a position in PDLI in Q1 2015 and held it in 3 quarters. The position peaked at $149K in Q3 2015. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

Ellington Management Group reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
Ellington Management Group sold 36,000 PDL BioPharma, Inc. shares in Q1 2016, an estimated $127K.
Ellington Management Group first reported a position in PDL BioPharma, Inc. in Q1 2015 and held it in 3 quarters.
Ellington Management Group's PDL BioPharma, Inc. position peaked at $149K in Q3 2015.
195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Ellington Management Group's 13F filing for Q1 2016, filed 16 May 2016.